Diffuse glioma molecular profiling with arterial spin labeling and dynamic susceptibility contrast perfusion MRI: A comparative study.

Autor:	Prysiazhniuk Y; Department of Pathophysiology, Second Faculty of Medicine, Charles University, Prague, The Czech Republic., Server A; Section of Neuroradiology, Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway., Leske H; Department of Pathology, Oslo University Hospital, Oslo, Norway., Bech-Aase Ø; Department of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway., Helseth E; Department of Neurosurgery, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Eijgelaar RS; Department of Neurosurgery, Amsterdam University Medical Center, Amsterdam, The Netherlands., Fuster-García E; Biomedical Data Science Laboratory, Instituto Universitario de Tecnologías de la Información y Comunicaciones, Universitat Politècnica de València, València, Spain., Brandal P; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway., Bjørnerud A; Department of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.; Center for Lifespan Changes in Brain and Cognition, University of Oslo, Oslo, Norway., Otáhal J; Department of Pathophysiology, Second Faculty of Medicine, Charles University, Prague, The Czech Republic., Petr J; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.; Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Amsterdam University Medical Center, Location VUmc, Amsterdam, The Netherlands., Nordhøy W; Department of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Jazyk:	angličtina
Zdroj:	Neuro-oncology advances [Neurooncol Adv] 2024 Jul 05; Vol. 6 (1), pp. vdae113. Date of Electronic Publication: 2024 Jul 05 (Print Publication: 2024).
DOI:	10.1093/noajnl/vdae113
Abstrakt:	Background: Evaluation of molecular markers ( IDH , p TERT , 1p/19q codeletion, and MGMT ) in adult diffuse gliomas is crucial for accurate diagnosis and optimal treatment planning. Dynamic Susceptibility Contrast (DSC) and Arterial Spin Labeling (ASL) perfusion MRI techniques have both shown good performance in classifying molecular markers, however, their performance has not been compared side-by-side. Methods: Pretreatment MRI data from 90 patients diagnosed with diffuse glioma (54 men/36 female, 53.1 ± 15.5 years, grades 2-4) were retrospectively analyzed. DSC-derived normalized cerebral blood flow/volume (nCBF/nCBV) and ASL-derived nCBF in tumor and perifocal edema were analyzed in patients with available IDH -mutation ( n = 67), p TERT -mutation ( n = 39), 1p/19q codeletion ( n = 33), and MGMT promoter methylation ( n = 31) status. Cross-validated uni- and multivariate logistic regression models assessed perfusion parameters' performance in molecular marker detection. Results: ASL and DSC perfusion parameters in tumor and edema distinguished IDH -wildtype (wt) and p TERT- wt tumors from mutated ones. Univariate classification performance was comparable for ASL-nCBF and DSC-nCBV in IDH (maximum AUROCC 0.82 and 0.83, respectively) and p TERT (maximum AUROCC 0.70 and 0.81, respectively) status differentiation. The multivariate approach improved IDH (DSC-nCBV AUROCC 0.89) and p TERT (ASL-nCBF AUROCC 0.8 and DSC-nCBV AUROCC 0.86) classification. However, ASL and DSC parameters could not differentiate 1p/19q codeletion or MGMT promoter methylation status. Positive correlations were found between ASL-nCBF and DSC-nCBV/-nCBF in tumor and edema. Conclusions: ASL is a viable gadolinium-free replacement for DSC for molecular characterization of adult diffuse gliomas. Competing Interests: There are no conflicts of interest to disclose. (© The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu